Acrux Ltd has released a press release.
Appendix 4E & Full Year Statutory Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Acrux
- Jublia Patent Litigation Settlement
- Appendix 4D and Half-Year Financial Report to 31 Dec 2018
- Acrux Receives $2.057m R&D Tax Incentive Rebate
- Acrux has second generic dossier accepted for review by FDA
- Acrux confirms patent challenge for generic of efinaconazole
Later from Acrux
- Acrux Ltd Investor Presentation and Full Year Results
- Receipt of first R&D Tax Incentive Rebate
- Appendix 4D and Half Year Financial Report
- Acrux Signs Licensing Agreement With TruPharma
- Acrux Signs Co-Development Agreement With Amring
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux